AROYA Crop Steering Expertise and Technology Provides Data-Driven Insights, Automation and Competitive Advantage for Successful Harvests

For cannabis operators, crop steering directs how their plants grow as well as their literal shape. Knowing how and when to manipulate light, climate and irrigation – the three foundational components of crop steering – is essential to balancing high yields and high quality.

Why do successful growers – from small craft farmers to the largest multistate operators – use data-driven and automated crop steering solutions? Because even the slightest adjustments to any number of factors can have huge effects on grows.

Data is the lifeblood of a plant growers, providing the intelligence to track how and when plants change from phase to phase and eliminate unknown variables, perfecting each run. The AROYA cultivation solution combines innovative hardware and software to deliver actionable insights from data, improving quality and yield – predictably and at scale.

With data-driven insights into each aspect of harvests, operators are empowered with the knowledge to not only increase yield per square foot, but also establish and employ repeatable best practices that ensure consistent quality. Identifying and adapting to various cues – from light, climate, and irrigation – encourages plants to produce bigger flowers with higher quality as well as finish getting their DNA out into the world before they die in an evolutionary selection process known simply by “stress.”

Generative stress is targeted intentional environmental pressure that encourages a plant’s behavior by focusing on reproductive parts. This not only finishes filling up space for future generations, but also removes unwanted elements like pests. In crop steering, this leads plants to produce almost double the count of bud sites. Also of note is that as every specific cultivar has its own feeding needs, automated crop steering maintains the balance between being too vegetative or too generative in terms of quality and yield.

Despite the increasing use of technology across the industry, many craft and independent farmers are sticking with their tried-and-true manual methods, like physically pouring run-off into milliliter cups, taking notes, and running tests by hand. And to their credit, they’re having success.

Unfortunately, failing to embrace cultivation and production technology will be their demise. In addition to competition from larger operators, many smaller outfits have gone all-in with crop steering, advanced drying and analytics.

Using crop steering tech provides access to easy-to-use, comprehensive tools to collect, analyze, and understand plants on a new level. As a result, they can bring out the most sought-out features of each cultivar.

The ability to consistently deliver the highest-quality products to market is the key to keeping and growing your customer base.

AROYA’s Cannabis Production Platform leverages crop steering solutions and cutting-edge IoT sensor technology to help plants grow better in different environments. Combining patented telemetry systems and software turns data into insights for each phase of growth.

Access to insights and analyses like rising terpenes, fluctuating THC levels, and total cannabinoids brings out the best of each strain. Hitting specific water content, moisture levels, and drying with precision brings the most out of cultivars.

For large operators like STIIIZY, AROYA makes it a lot easier to manage multiple facilities and assign tasks remotely, and to know if at any time a grow is operating outside of certain thresholds. Crop steering enables scalability and growth for STIIIZY, the third best-selling brand in the United States and the number one brand in California – the largest cannabis market in the world.

Analyzing historical records for each stage optimizes growth across all areas, which is how operators like STIIIZY consistently produce runs with higher yields while maintaining production levels and quality. AROYA’s technology enhances cultivation practices – which are repeatable and are implemented in every STIIIZY facility.

Sean Oganesyan, Senior Vice President of Cultivation with STIIIZY, credits the company’s success to data intelligence real-time insights secured from AROYA’s Cannabis Cultivation and Production Platform, which allows him to manage multiple facilities from a single location.

“The concept of sensor density is important, as more sensors deployed across our grows ensures better results and data-driven decisions that eliminate unknown variables. I don’t like variables. I dot all my i’s and cross all my t’s – that’s my military background. I need answers, I need to know exactly what’s going on, I need to be in full control of a situation, and that gave me control. That’s why I’m comfortably sitting here and talking to you today. I’m not going around somewhere in a plane or flying to some different state because somebody messed something up in my irrigation.”

“The communication with the AROYA team is fluid; we both understood what we must gain from each other, and this helps STIIIZY bring good products to the market.”

AROYA’s IoT sensors installed at customer facilities not only observes – but also enables digital interactions between stakeholders involved in every part of the cannabis cultivation process – from selecting nutrients to use during vegetative periods down to dietary instructions once flowerheads start forming on branches.

Cultivators rely on giving plants an ideal amount of light each day; the AROYA platform provides access to this data, delivering insights on exactly what percentiles lights need to stay at with specific plants and the amount of coverage within each room, allowing growers to adjust lighting quicker using data-driven decisions.

With BACnet access to AROYA with STIIIZY’s fully controlled system, Oganesyan can communicate with his controls with AROYAs sensors to make decisions for plants based on real-time data and recipes assigned to specific cultivars, adjusting things like irrigation based on EC readings in a plant’s substrate.

“AROYA gives me full control of my irrigation cycles,” said Oganesyan. “I have the full analytics team behind it continuously monitoring multiple locations. All my grows are literally run through my headquarters in downtown Los Angeles.”

Operators must be able to account for everything that’s going on inside their facilities, and even if you have the tightest controls, there’s still going to be variables that are just inherent to the cannabis industry, such as plant variation.

Oganesyan touted AROYA’s differentiators and superior technology among the biggest selling points for selecting AROYA over other systems.

“If you got a company that makes sensors and you got all the other companies buying those sensors, white labeling those sensors and want to put their name on it, I just go straight to the source.”

ABOUT AROYA

AROYA is a cannabis production platform that combines industry-leading hardware and software to help cultivators increase yield, scale operations, and achieve consistent quality. Based in Pullman, Washington, and a division of METER Group, Inc., AROYA optimizes and demystifies the entire cannabis production process from seed to package.

For additional information, please visit AROYA.io.

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Third-Party Content

The CNW website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the CNW Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of CNW or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and CNW does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by CNW providing you with this internet portal that makes accessible to you the ability to view third party content through the CNW site, CNW does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. CNW expressly disclaims liability relating to such third-party content. CNW and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, CNW reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://www.cannabisnewswire.com/disclaimer.

420 with CNW — Experts Say Federal Court Ruling in Maine Could Pave Way for Interstate Cannabis Commerce

Last week, a federal appellate court ruled that the law prohibiting nonresidents in Maine from owning medical cannabis businesses in the state violated the United States’ constitution. Stakeholders in the industry have been monitoring the case keenly, with many arguing that the dormant commerce clause of the constitution applies to the cannabis industry, despite ongoing federal marijuana prohibition.

Legal experts believe that this ruling may have extensive implications for interstate marijuana commerce, with some noting that it could create potential complications for social equity programs. In the 2 to 1 ruling, the U.S. Court of Appeals for the First Circuit stated that while marijuana was illegal federally, Congress had acknowledged the existence of a medical cannabis market via the Rohrabacher–Farr amendment, which barred the Department of Justice from interfering with state-legal medical marijuana markets using its funds. The ruling added that in approving this legislation in 2014 and renewing it yearly since then, Congress had also acknowledged that the cannabis market could continue existing in some circumstances without federal criminal enforcement.

The state of Maine had in the past eliminated the residency requirement for its adult-use cannabis market. If the appellate court ruling is not appealed, interested parties will now have the chance to operate and own medical cannabis dispensaries in the state.

It should be noted that this ruling is limited in scope because it only directly affects states within its jurisdiction, which include Maine, Rhode Island, Puerto Rico, New Hampshire and Massachusetts. Despite this, the ruling has still caught the attention of many in the country, as more states move to enact legislations to lay the groundwork for interstate cannabis commerce.

For instance, Senate President Nicholas Scutari of New Jersey recently filed a measure that would permit the governor to enter into agreements with other legal states to export and import marijuana. This measure is similar to another interstate commerce initiative that was filed and signed into law in 2019 by Governor Kate Brown of Oregon.

It is important to note that these agreements can only be drawn up if the state attorney general (AG) verifies that the measure’s implementation won’t bring about considerable legal risk to the state, and the law can only take effect if the Department of Justice issues guidance authorizing such activity or if the federal law changes.

Meanwhile, a measure introduced by Sen. Anna Caballero of California, which would permit the governor to enter into interstate cannabis commerce agreements, was cleared for floor consideration by an assembly committee recently.

When cannabis interstate commerce finally becomes legal, multistate operators such as Flora Growth Corp. (NASDAQ: FLGC) will find an easier time optimizing their operations across the different markets in which they wish to have a presence.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — DOT Tables New Guidelines on CBD on the Certification of Commercial Drivers

The cannabidiol (CBD) revolution has been fantastic to behold. In just a few short years, the cannabis extract went from virtual anonymity to being one of the most searched-for items on the web. CBD is said to have a plethora of medical applications, including alleviating anxiety, chronic pain and insomnia, and it has been subject to significant consumer and scientific interest in recent years.

However, cannabidiol use is still frowned upon by plenty of employers, including the federal government. This is despite the fact that unlike delta-9 THC, the main psychoactive agent in cannabis, CBD does not intoxicate users. In the same vein, a federal agency recently declared that commercial drivers who consume CBD are doing so “at their own risk.” The agency made this declaration in a federal handbook meant to guide medical examiners who issue certifications from the U.S. Department of Transportation (DOT).

Issued by the Federal Motor Carrier Safety Administration (FMCSA), the handbook is meant to guide medical examiners who carry out physical examinations on interstate commercial drivers. The handbook acknowledges that while CBD products should have less than 0.3% THC per dry weight as outlined in federal regulations, physical exam certifications can still be impacted by consuming CBD products.

The agency notes that drivers whose employment requires them to undergo physical examinations and receive certification from the DOT “cannot be physically qualified” if they use cannabis even if their home state allows medical and recreational cannabis use.

So why are drivers who use cannabidiol products at risk even though they typically don’t contain enough THC to intoxicate them? Poor regulation.

Since the CBD sector’s inception, industry stakeholders, CBD businesses and even lawmakers have complained about the lack of regulation. Even though many have repeatedly urged the U.S. Food and Drug Administration to create a comprehensive regulatory framework for years, the FDA has dragged its feet, resulting in a barely regulated industry flush with dishonest players that aren’t always concerned with quality control.

Studies have found that mislabeling, contamination and medical fraud are common in the nascent CBD sector. Researchers found that plenty of cannabis products are not only contaminated with more THC than is legally allowed, but they also contain harmful substances such as bacteria, heavy metals and pesticides. The FMCSA handbook explained that there is little federal oversight to make sure that CBD products are actually true to their labeling and that their claims of having less than 0.3% THC are accurate.

This means that commercial drivers could potentially build up enough THC to fail physical examinations. The agency emphasized that contamination due to CBD use will not be a viable excuse. Even so, the FMCSA handbook urged examiners to evaluate each driver on a case-by-case basis.

The solution to these guidelines that aren’t in tandem with the law in states where marijuana is legal can only be resolved once reforms are instituted at the federal level. Only then will consumers who buy cannabis products from legitimate companies such as American Cannabis Partners finally relax in the knowledge that indulging in a legal product will not cause them trouble with their employers.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program and Recent FDA Confirmation Position It for Favorable Valuation

  • Lexaria is a global innovator of drug delivery platforms, including its patented DehydraTECH(TM) technology
  • The company recently released information that would help its stakeholders research and understand how biotech and pharmaceutical companies are valued
  • Based on some of the methodologies used in valuation, Lexaria is positioned favorably as its DehydraTECH-processed CBD for the treatment of hypertension has successfully reached the IND application stage, with the program recently receiving an additional boost
  • The FDA agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, for its hypertension program

As a follow-up to recent coverage by Zacks Small-Cap Research, which valued the company at $15.00 (https://cnw.fm/obZ1e), global innovator Lexaria Bioscience (NASDAQ: LEXX) provided information to its stakeholders that would help them conveniently research and understand different non-affiliated third-party sources and their methodologies for valuing biotech and pharmaceutical companies.

“Valuation of equities is a complex task with innumerable risks and rewards that include far-reaching macro events as well as company-specific developments. It is nearly impossible to foresee all risks and rewards, but underlying logic-based evaluation is one way to provide a realistic framework of expectations that investors can use in their analysis,” the August 11 press release reads (https://cnw.fm/DGYh2).

One of the logic-based evaluations considers the stage at which a company’s drug development program has reached. According to the U.S. Food and Drug Administration (“FDA”), there are five steps to the drug development process: Discovery and Development, Preclinical Research, Clinical Research, FDA Drug Review, and, finally, FDA Post-Market Drug Safety Monitoring. However, not more than about 250 of 5,000-10,000 compounds tested during the Discovery stage successfully transition to the third step. Against this backdrop, Lexaria stands out, having completed the first two steps with its DehydraTECH-CBD for hypertension treatment, with favorable results to boot.

The company’s first advanced human clinical study (“HCS”) for hypertension, conducted in 2018, for example, showed that DehydraTECH drug delivery technology delivered 317% more CBD to the blood at 30 minutes. Later HCS’s evidenced rapid and sustained drop in blood pressure (HYPER-H21-1), up to a 23% average reduction in overnight blood pressure and reduced arterial stiffness (HYPER-H21-2), and a 41% overall reduction in pulmonary artery systolic pressure (“PASP”) in male subjects (HYPER-H21-3). Lexaria is set to announce results from its fourth HCS – HYPER-H21-4 – in Q4 2022 (https://cnw.fm/caWiK).

If the HYPER-H21-4 study were registered with the FDA, Lexaria notes, it would possibly be a Phase 1B or 2A study. This information lends color to the company’s valuation going by a guide prepared by Bay Bridge Bio, which notes that a company’s valuation increases as its drug development progresses from Phase 1 through Phase 3. For example, at the start of a Phase I trial, a biotech company’s valuation would be $88 million, a figure that would then rise to $248 million at the start of Phase 2 study, finally eclipsing the $1 billion mark to settle at $1.119 billion when the Phase III trial begins. The figures increase further following an FDA approval of the drug candidate.

Considering the FDA’s recent confirmation that it agreed with Lexaria’s proposal to pursue a 505(b)(2) new drug application (“NDA”) regulatory pathway, an abbreviated pathway, the company’s accelerated drug development program for hypertension therapeutics could wend way to a multi-billion-dollar valuation in due course. The pharmaceutical industry is rife with examples of such possibilities.

In March, for example, Pfizer Inc. (NYSE: PFE) completed the acquisition of clinical-stage company Arena Pharmaceuticals for a total consideration of $6.7 billion. At the time of the acquisition, Arena was expecting results for its Phase 3 trial undertaken to evaluate the safety and efficacy of the etrasimod drug candidate in patients with active ulcerative colitis (https://cnw.fm/LRYMc).

As a December 2021 report by accounting firm PwC notes, big pharma is set to spend anywhere between $5 billion and $15 billion and, in some cases, as much as $50 billion in 2022 to purchase promising biotech companies and their IP, as they seek to bring on board in new drugs that can become serious revenue generators (https://cnw.fm/3KBKG). Such acquisitions attest that biotech companies with little to no revenue can still be worth billions.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Mothers in Indonesia Fight for Their Children to Have Access to Medical Cannabis

Medical cannabis has been found to be a viable treatment for a wide variety of medical conditions in recent years. Studies have revealed that the plant can be effective against health issues such as chronic pain, anxiety, insomnia and depression. Furthermore, the US Food and Drug Administration has approved the use of a CBD-based drug called Epidiolex to treat seizures in pediatric epilepsy.

In Indonesia, a group of mothers is fighting to get their children access to cannabis, a plant they say could alleviate the pain caused by illnesses such as cerebral palsy. Pika Sasi Kirana was diagnosed with cerebral palsy when she was around five years old despite being a relatively healthy child for most of her young life.

Pika’s mother, Santi Warastuti, said the little girl started vomiting and fainting regularly, which prompted her parents to take her to a hospital and learn of her condition. Her health deteriorated significantly once the parents received a written diagnosis, with physicians struggling to halt the progression of the condition or find a way to give Pika a little comfort.

None of the different medications and doses that the doctors prescribed for Pika were effective, her mother said. By the time Pika required round-the-clock care and could barely do anything for herself, Warastuti was desperate for a medication that could at least make her daughter feel more comfortable.

Even though Indonesia is famous for its tough drug laws, Warastuti turned her attention to one of the most controversial drugs on the planet: medical marijuana. Warastuti, who used to work as a fashion designer, had first heard of medical cannabis when her European boss told her about the drug’s wide range of medical applications and that medical cannabis use was steadily gaining traction in Europe.

When she moved back to Yogyakarta, her hometown, Warastuti met Dwi Pratiwi, another mother interested in medical cannabis treatments for her child. Pratiwi had taken her son Musa to Australia for medical marijuana treatment and was a plaintiff in a Constitutional Court case to legalize cannabis in Indonesia. Although Musa has since died, Pratiwi said that she saw firsthand how medical cannabis helped to ease Musa’s muscular atrophy and made it easier for him to fall asleep.

The efforts of Pratiwi, Warastuti and another mother whose child has cerebral palsy to legalize cannabis have been unsuccessful so far, with the country’s Constitutional Court rejecting a motion to review Indonesia’s 2009 narcotics law. Even so, Warastuti was happy that the court ordered the government to research the medical uses of cannabis despite rejecting the mothers’ motion to legalize medical marijuana.

If only the plight of these Indonesian children could be considered and the needed reforms made, parents of children in need of medical cannabis could one day make use of advanced technologies, including the vertical gardening equipment manufactured by companies such as Advanced Container Technologies Inc. (OTC: ACTX) to cultivate their own high-quality medicinal marijuana to cut the costs of treating children.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Uncertainty Grows Over When Germany Will Legalize Marijuana

Germany has spent the past couple of months mulling over whether or not it should legalize cannabis, a move that would potentially turn the country into the world’s largest market for legal cannabis. With Germany’s left-liberal government pushing on with plans to legalize adult-use cannabis in the country, the coalition government has undertaken a series of public hearings with cannabis growers, economists and health experts to help inform the legalization process.

If Germany chooses to legalize recreational cannabis, the move could put pressure on its neighbors to follow its lead and create enough momentum to change the UN convention barring the cultivation and sale of cannabis. The coalition government recently declared that it was going to introduce “the controlled supply of recreational cannabis” to adults via licensed cannabis shops. However, turning these words into a nationwide cannabis industry is proving to be quite a challenge.

Legalizing cannabis would require input from nearly every federal government ministry, making the entire legislative process extremely complex and time consuming. Drug and addiction commissioner Burkhard Blienert says that efforts to legalize cannabis would have to involve policing, agriculture, tax issues and youth protection, to name a few. The ideal cannabis industry would be one that allows adults to purchase cannabis from licensed specialty shops while prioritizing public health and the protection of minors.

Given that cannabis is in extremely high demand, a legal market is expected to attract millions of consumers, in turn generating billions of dollars in taxes. Based on estimates that show most of the 4 million Germans who consume cannabis do so occasionally, Dusseldorf-based economist Justus Haucap expects cannabis to have a market value of around €4 billion ($3.97 billion) to €5 billion ($4.96 billion) or about 400 tons.

During an expert meeting held at the Health Ministry last year, Haucap estimated that the possible savings made by the police force and judiciary coupled with possible revenue from cannabis taxes and social security contributions could add up to almost $5 billion per year. He was one of nearly 200 local and international experts who met to discuss marijuana legalization. According to drug commissioner Blienert, the government is expected to draft a cannabis bill based on key points before deliberating it in parliament.

He says that once the federal government has crafted a comprehensive cannabis bill, it will be up to parliament to pass the bill and facilitate the creation of a nationwide adult-use cannabis industry. According to industry representative Heitepriem, players in a potential German cannabis industry wouldn’t be able to participate in international trade due to European regulations and UN conventions. This means Germany will have to source all its cannabis internally, a feat that will require significant investment and a lead time of one to two years to allow producers to ramp up production.

By the time the German marijuana market is launched, its players could lag far behind companies such as Prime Harvest Inc., which are already operational in North America and well positioned to expand should laws change at the federal and international levels.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Advanced Container Technologies Inc. (ACTX) Featured in Top News Guide

Advanced Container Technologies (OTC: ACTX) today announced that it was featured in Top News Guide’s “Stock in Focus”. The publication wrote, “Following a key announcement from the company yesterday, it might be a good move for investors to take a bit of an interest in Advanced Container Technologies…” According to the report, ACTX stock is above the 20-day and 50-day moving averages of $0.60 and $0.63, respectively. Top News also referenced a recent ACTX press release regarding GrowPods, hydroponic modular farms that can be located almost anywhere. “The addition of one or two GrowPods is going to allow farmers to move into profitable fruits or vegetables, which offer higher margins throughout the year,” the report reads.

“We are pleased that GrowPods are receiving national attention,” said Douglas Heldoorn, CEO of Advanced Container Technologies. “GrowPods offer a way for farmers to cultivate high-quality crops and create new revenue streams, year-round. With so many small family farmers struggling, GrowPods offer a way to quickly begin growing high-margin ultra-clean crops that can usually command significantly higher prices at retail.”

To view the full press release, visit https://cnw.fm/EXLGB

About Advanced Container Technologies Inc.

Advanced Container Technologies is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer(R), that store and grind pharmaceuticals, herbs, teas and other solids or liquids. For more information, visit the company’s website at www.AdvancedContainerTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to ACTX are available in the company’s newsroom at https://cnw.fm/ACTX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Gallup Poll Finds Americans Think Cannabis Better than Alcohol for Society

Consecutive surveys over the past couple of years have revealed that attitudes toward cannabis have been steadily shifting toward the positive. After decades of criminalization, over policing, harsh sentencing and anti-cannabis propaganda, a large swathe of the population believed cannabis was just as dangerous as hard-core drugs such as cocaine and heroin.

But as cannabis reform has swept over the country for the past two decades, consumers have been increasingly inclined to shed their preconceived notions about cannabis. This is largely due to the fact that studies have shown that the controversial plant has a wide range of medical applications.

A new poll by Gallup, which has conducted several cannabis-related surveys in the past, shows that Americans believe that marijuana is much better for people and society compared to alcohol. The survey found that the number of Americans who believe cannabis has a positive impact on users and the community at large is more than double the number of Americans who have the same opinion about alcohol. Furthermore, the poll revealed that cannabis users were much more likely to extoll its pros compared to a small portion of alcohol drinkers who believed alcohol had a positive impact.

A reported 53% of the Americans surveyed said that cannabis had a “positive impact” on users compared to 45% who said it had a negative impact. Regarding the plant’s impact on society, 49% said that cannabis had a good impact while 50% said its impact on society has been negative. On the other hand, 27% of the people who were polled said alcohol was good for the drinker, and 23% stated that alcohol had a positive societal impact.

A majority — 75% — believed that alcohol has a net negative impact on society, and 71% said that it isn’t good for individual drinkers either. This is despite the fact that the manufacture and sale of alcohol is legal at the federal level while cannabis is still outlawed.

Some 70% of people who had used cannabis in the past were far more likely to say that it had a positive impact, and 66% believed it had a positive societal impact compared to 32% and 27% of drinkers who felt alcohol had a positive impact on consumers and society respectively.

An estimated 37% of non-cannabis users said cannabis was good for users, and 27% said it was good for society at large. In comparison, only 14% of non-alcohol-drinkers said it had a net positive impact on drinkers and society,

Overall, the Gallup poll shows that people’s perceptions of these two drugs don’t seem to be in line with federal law; the poll revealed a stark contrast between how the public sees cannabis vs. alcohol.

That shift in attitude toward marijuana is evident in the way the sales of licensed marijuana companies such as Cannabis Strategic Ventures Inc. (OTC: NUGS) are generally on an upward trajectory despite the industry being flooded by plenty of players.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — YouGov Survey Finds 20% of Americans Have Changed Stance on Drug Policy

A new survey by YouGov has revealed that public opinion on drug policy seems to be in line with the changing legal landscape. With dozens of states now allowing recreational and medical cannabis use, a majority of Americans have access to some kind of cannabis product. The YouGov poll found that two in five Americans have changed their views on drug policy, shifting their attitudes in a more liberal direction amid sweeping cannabis reform.

The poll questioned respondents on a variety of topics, asking whether they had changed their minds on some issues, how their political views had changed, and what influenced them to consider the issue from a different angle. Overall, the respondents were polled on 11 hot-button subjects, with drug policy emerging as the second most common issue that people said they had changed their stances on.

Some 41% of respondents said that their views on drug policy had evolved, following 42% who said that their views on foreign policy had changed. An estimated 32% had changed their opinions on healthcare, 31% changed their opinions on immigration, and 28% shifted their views on gun control. The poll also asked respondents whether they had changed their views about the death penalty, same-sex marriage, racial discrimination, abortion, free speech and climate change.

Of those who shared their views on drug policy, 48% reported that they had become “more liberal,” 26% said they were “more conservative,” and 26% reported that their views had “changed in some way.” However, the YouGov survey did not cover specific drug policy issues such as cannabis legalization, expanding access to psychedelics for medical use and safe consumption sites for federally controlled drugs.

When asked what made them change their minds on drug policy, 50% said it was due to “new facts and information.” Some 47% said their opinions shifted as they matured and gained more insights about the world while 39% said world events caused them to reconsider their opinions on drug policies. An estimated 32% of the respondents changed their minds on drug policy due to conversations they had with other people, 33% due to personal experience with the issue, and 14% due to changes in their religious or moral views.

Even though the poll didn’t specifically discuss marijuana, previous surveys have found that people’s opinions on cannabis reform have shifted over the years. A 2021 poll from Gallup revealed that 68% of Americans supported recreational cannabis legalization compared to 56% in 1969. Another pair of Gallup surveys found that more Americans believe that cannabis has a positive impact on consumers and society at large compared to alcohol.

That viewpoint may cause growing numbers of consumers to switch to consuming marijuana rather than alcohol, a change that could mean entities such as Flora Growth Corp. (NASDAQ: FLGC) may have lots of opportunities to expand into different markets around the country.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Former Cannabis Regulators Want 10 Social-Equity Provisions Included in Marijuana Banking Bill

Most, if not all, state cannabis legalization bills contained social-equity provisions designed to reinvest in communities that had been disproportionately harmed by the war on drugs. These social-equity provisions would fund a variety of community-based programs to aid communities of color in a variety of facets and make it easier for people who were directly or indirectly affected by the drug war to break into the cannabis industry.

As the end of Congress approaches, policymakers, cannabis reform advocates and industry stakeholders are hoping to pass some kind of cannabis legislation before January, even if they have to compromise in some areas. One bill that could pass is cannabis banking legislation that would finally grant the state-legal industry access to banking services. Cannabis businesses are currently unable to obtain banking services due to the drug’s controlled status at the federal level, forcing those businesses to operate on a cash-only basis and limiting their access to capital and federal financial aid.

The bipartisan Secure and Fair Enforcement Banking (SAFE) Act would allow banks to service cannabis businesses without fear of federal reprisal. But before the bill is signed into law, the Cannabis Regulators of Color Coalition (CRCC) would like lawmakers to ensure it prioritizes social equity. In a paper published by The Ohio State University (OSU), Mortiz College of Law, CRCC outlines 10 social-equity provisions that would make the bill more palatable to lawmakers such as Senate Majority Chuck Schumer who prefer widespread, justice-focused reform.

The CRCC would like the banking bill to call for amendments that would make it necessary for financial institutions to prove that they are compliant with antidiscrimination laws before they can receive cannabis-related protections, for starters. The coalition says that the legislation will require “additional legislative amendments” that directly address the issues associated with equitable and fair access to critical financial services.

If not, the coalition states, small and minority-owned marijuana businesses that already have limited access to banking services and capital will continue to suffer. The CRCC’s paper comes weeks after Senate Majority Leader Chuck Schumer officially filed his long-awaited Cannabis Administration and Opportunity Act (CAOA). Although Schumer and other key players have not supported cannabis banking in the past, they have indicated that they are willing to compromise.

Schumer is currently holding talks with Senator Cory Booker and other key lawmakers regarding a possible compromise package of modest cannabis reforms that would include cannabis banking provisions.

Any reforms, such as allowing financial institutions to work with cannabis industry actors, would go a long way towards easing the environment within which companies such as Advanced Container Technologies Inc. (OTC: ACTX) operate.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.